Ladenburg Thalmann Maintains Buy on Cognition Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov maintains a 'Buy' rating on Cognition Therapeutics (NASDAQ:CGTX) but has lowered the price target from $10 to $6.
August 14, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target, Ladenburg Thalmann maintains a 'Buy' rating on Cognition Therapeutics, indicating continued confidence in the company's potential.
The lowered price target may initially seem negative, but the maintained 'Buy' rating indicates that the analyst still sees potential in the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100